<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">LAMIVUDINE <img border="0" src="../images/pr.gif"/></span><br/>(lam-i-vu'deen)<br/><span class="topboxtradename">Epivir, </span><span class="topboxtradename">Epivir-HBV, </span><span class="topboxtradename">Heptovir <img border="0" src="../images/maple.gif"/><br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">antiretroviral agent</span>; <span class="classification">nucleoside reverse transcriptase inhibitor (nrti)</span><br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>100 mg, 150 tablets; 5 mg/mL, 10 mg/mL oral solution</p>
<h1><a name="action">Actions</a></h1>
<p>Lamivudine is a synthetic nucleoside analog.</p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Its phosphorylated metabolite (L-TP) inhibits the transcription of the HIV viral RNA chain.</p>
<h1><a name="uses">Uses</a></h1>
<p>HIV infection in combination with zidovudine; treatment of chronic hepatitis B.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to lamivudine, lactation.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Renal impairment, pregnancy (category C), children.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">HIV Infection</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 150 mg b.i.d.<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span>
<i>3 mo16 y</i>, 4 mg/kg b.i.d. (max: of 150 mg b.i.d.)<br/><br/><span class="impairmenttitle">Renal Impairment</span><br/>Cl<sub>cr</sub> 3049 mL/min: 150 mg q.d.; 1529 mL/min: 150 mg first dose, then 100 mg q.d.; 514 mL/min: 150 mg first dose,
               then 50 mg q.d.; <br/><span class="indicationtitle">Chronic Hepatitis B</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 100 mg q.d.<br/><br/><span class="impairmenttitle">Renal Impairment</span><br/>Cl<sub>cr</sub> 3049 mL/min: 100 mg first dose, then 50 mg q.d.; 1529 mL/min: 100 mg first dose, then 25 mg q.d.; 514 mL/min:
               35 mg first dose, then 15 mg q.d.; <br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give Epivir b.i.d. in combination with AZT. The recommended dose for adults who weigh NOT give in combination with AZT.
         </li>
<li>Store solution at 2°25° C (36°77° F) tightly closed.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span>
<span class="speceff-common">Neuropathy, insomnia,</span> sleep disorders, <span class="speceff-common">dizziness,</span> depression, <span class="speceff-common">headache,</span> fatigue, <span class="speceff-common">fever, chills</span>. <span class="typehead">GI:</span>
<span class="speceff-common">Nausea, diarrhea,</span> vomiting, anorexia, abdominal pain, cramps, dyspepsia, increased LFTs (ALT, amylase), <span class="speceff-life">hepatomegaly with steatosis</span>. <span class="typehead">Hematologic:</span> Neutropenia, anemia, thrombocytopenia. <span class="typehead">Musculoskeletal:</span> Myalgia, arthralgia, malaise, pain. <span class="typehead">Skin:</span> Rash. <span class="typehead">Respiratory:</span> Nasal symptoms, cough. <span class="typehead">Metabolic:</span>
<span class="speceff-life">Lactic acidosis</span>. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead"> Drug:</span>  Increases the <i>C</i>
<sub>max</sub> of <b>zidovudine.</b>
<b>Trimethoprim-sulfamethoxazole</b> increases serum levels of lamivudine. Increased risk of lactic acidosis in combination with other <span class="classification">reverse transcriptase inhibitors</span> and <span class="classification">antiretroviral agents</span>. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Rapidly absorbed from GI tract (86% reaches systemic circulation). <span class="typehead">Distribution:</span> Low binding to plasma proteins. <span class="typehead">Metabolism:</span> Minimal metabolism. <span class="typehead">Elimination:</span> Excreted primarily unchanged in urine. <span class="typehead">Half-Life:</span> 24 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor children closely for S&amp;S of pancreatitis; if they occur, immediately stop drug and notify physician.</li>
<li>Lab tests: Monitor CBC with differential, kidney &amp; liver function, and serum amylase throughout therapy.</li>
<li>Monitor for and report all significant adverse reactions.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report any of the following immediately: nausea, vomiting, anorexia, abdominal pain, jaundice.</li>
<li>
            							Note: The long-term effects of lamivudine are unknown.
            						
         </li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>